MX2020006224A - Metodos y terapia combinada para el tratamiento del cancer. - Google Patents
Metodos y terapia combinada para el tratamiento del cancer.Info
- Publication number
- MX2020006224A MX2020006224A MX2020006224A MX2020006224A MX2020006224A MX 2020006224 A MX2020006224 A MX 2020006224A MX 2020006224 A MX2020006224 A MX 2020006224A MX 2020006224 A MX2020006224 A MX 2020006224A MX 2020006224 A MX2020006224 A MX 2020006224A
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapy
- methods
- treat cancer
- combination
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente invención se refiere a un método para el tratamiento del cáncer mediante la administración de una terapia combinada que comprende una combinación de un inhibidor de MEK y un antagonista de unión al eje PD-1, o una combinación de un inhibidor de MEK y un inhibidor de PARP, o una combinación de un inhibidor de MEK y un antagonista de unión al eje PD-1 y un inhibidor de PARP a un paciente que lo necesita.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762607190P | 2017-12-18 | 2017-12-18 | |
PCT/IB2018/060181 WO2019123207A1 (en) | 2017-12-18 | 2018-12-17 | Methods and combination therapy to treat cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006224A true MX2020006224A (es) | 2020-09-03 |
Family
ID=65237078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006224A MX2020006224A (es) | 2017-12-18 | 2018-12-17 | Metodos y terapia combinada para el tratamiento del cancer. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210077463A1 (es) |
EP (1) | EP3727385A1 (es) |
JP (1) | JP2021507904A (es) |
KR (1) | KR20200101951A (es) |
CN (1) | CN111629729A (es) |
AU (1) | AU2018389196A1 (es) |
BR (1) | BR112020011287A2 (es) |
CA (1) | CA3085812A1 (es) |
IL (1) | IL275517A (es) |
MX (1) | MX2020006224A (es) |
SG (1) | SG11202004629PA (es) |
TW (1) | TW201938165A (es) |
WO (1) | WO2019123207A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019006504A2 (pt) * | 2016-10-06 | 2019-06-25 | Merck Patent Gmbh | regime de dosagem de avelumabe para o tratamento de câncer |
MX2020006866A (es) * | 2017-12-27 | 2020-11-11 | Tesaro Inc | Metodos para tratar el cancer. |
AU2021268579A1 (en) * | 2020-05-04 | 2022-12-01 | Merck Sharp & Dohme Corp. | Methods of treating cancer using a combination of a PD-1 antagonist, a chemoradiation therapy and a parp inhibitor |
WO2023064900A1 (en) * | 2021-10-15 | 2023-04-20 | Igm Biosciences, Inc. | Methods of use of multimeric anti-pd-l1 binding molecules |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
NZ535158A (en) | 2002-03-13 | 2007-06-29 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US8012976B2 (en) | 2008-08-06 | 2011-09-06 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
AU2011212928B2 (en) | 2010-02-03 | 2016-06-23 | Medivation Technologies Llc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency |
WO2011097602A1 (en) | 2010-02-08 | 2011-08-11 | Biomarin Pharmaceutical Inc. | Processes of synthesizing dihydropyridophthalazinone derivatives |
SG189939A1 (en) | 2010-10-21 | 2013-06-28 | Biomarin Pharm Inc | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
AU2013235596B9 (en) * | 2012-03-20 | 2017-12-14 | Amgen Inc. | Combination therapy of a MEK inhibitor and IGF1R inhibitor |
CA3079071C (en) | 2012-10-19 | 2022-06-07 | Array Biopharma Inc. | Preparation of crystallized benzimidazole derivative as mek inhibitor and formulation comprising same |
WO2015069851A1 (en) | 2013-11-07 | 2015-05-14 | Biomarin Pharmaceutical Inc. | Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes |
TR201901507T4 (tr) * | 2014-02-04 | 2019-02-21 | Merck Sharp & Dohme | Kanseri tedavi etmeye yönelik bir pd-1 antagonsitinin ve bir vegfr inhibitörünün kombinasyonu. |
US20160009805A1 (en) * | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
EP3174855B1 (en) | 2014-07-31 | 2023-05-10 | Medivation Technologies LLC | Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
EP3359157A4 (en) * | 2015-10-06 | 2019-05-15 | The Wistar Institute Of Anatomy And Biology | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METASTASIS AND RESISTANT TUMORS AND CANCERS |
SG11201803462PA (en) | 2015-10-26 | 2018-05-30 | Medivation Tech Llc | Treatment of small cell lung cancer with a parp inhibitor |
GB201704267D0 (en) * | 2017-03-17 | 2017-05-03 | Genome Res Ltd | Novel biomarker |
CA3063201A1 (en) * | 2017-05-09 | 2018-11-15 | Tesaro, Inc. | Combination therapies for treating cancer |
-
2018
- 2018-12-14 TW TW107145192A patent/TW201938165A/zh unknown
- 2018-12-17 BR BR112020011287-9A patent/BR112020011287A2/pt not_active IP Right Cessation
- 2018-12-17 AU AU2018389196A patent/AU2018389196A1/en not_active Abandoned
- 2018-12-17 CA CA3085812A patent/CA3085812A1/en not_active Abandoned
- 2018-12-17 CN CN201880081709.5A patent/CN111629729A/zh active Pending
- 2018-12-17 US US16/772,306 patent/US20210077463A1/en not_active Abandoned
- 2018-12-17 MX MX2020006224A patent/MX2020006224A/es unknown
- 2018-12-17 SG SG11202004629PA patent/SG11202004629PA/en unknown
- 2018-12-17 WO PCT/IB2018/060181 patent/WO2019123207A1/en unknown
- 2018-12-17 JP JP2020533843A patent/JP2021507904A/ja active Pending
- 2018-12-17 EP EP18840051.9A patent/EP3727385A1/en not_active Withdrawn
- 2018-12-17 KR KR1020207020801A patent/KR20200101951A/ko active Search and Examination
-
2020
- 2020-06-18 IL IL275517A patent/IL275517A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2018389196A1 (en) | 2020-06-11 |
EP3727385A1 (en) | 2020-10-28 |
BR112020011287A2 (pt) | 2020-11-24 |
WO2019123207A1 (en) | 2019-06-27 |
JP2021507904A (ja) | 2021-02-25 |
US20210077463A1 (en) | 2021-03-18 |
KR20200101951A (ko) | 2020-08-28 |
IL275517A (en) | 2020-08-31 |
TW201938165A (zh) | 2019-10-01 |
CN111629729A (zh) | 2020-09-04 |
SG11202004629PA (en) | 2020-07-29 |
CA3085812A1 (en) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202110554B (en) | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors | |
MX2020006224A (es) | Metodos y terapia combinada para el tratamiento del cancer. | |
MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
MX2022001757A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer. | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2017005929A (es) | Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit. | |
MX2018014435A (es) | Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer. | |
MY194586A (en) | Anti-garp antibody | |
MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
MX2022008868A (es) | Tratamiento del cancer con tg02. | |
EA201490369A1 (ru) | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek | |
MX2017000546A (es) | Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek. | |
MX2020003361A (es) | Combinacion de un inhibidor parp y un antagonista de union al eje pd-1. | |
MX2015014591A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. | |
MX2017012824A (es) | Tratamiento de cáncer de pulmón con inhibidores de glutaminasa. | |
MX2020013808A (es) | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. | |
MX2020011684A (es) | Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer. | |
MX2019002108A (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
MX2017009246A (es) | Farmaco de combinacion. | |
MX2020001727A (es) | Terapia de combinacion. | |
MX2019013862A (es) | Terapia de combinacion. | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2018005233A (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer. | |
ZA202300875B (en) | Kat6 inhibitor methods and combinations for cancer treatment |